ECSP055626A - NEW CONJUGATES OF EFFECTORS, PROCEDURES FOR PREPARATION AND PHARMACEUTICAL USE - Google Patents

NEW CONJUGATES OF EFFECTORS, PROCEDURES FOR PREPARATION AND PHARMACEUTICAL USE

Info

Publication number
ECSP055626A
ECSP055626A EC2005005626A ECSP055626A ECSP055626A EC SP055626 A ECSP055626 A EC SP055626A EC 2005005626 A EC2005005626 A EC 2005005626A EC SP055626 A ECSP055626 A EC SP055626A EC SP055626 A ECSP055626 A EC SP055626A
Authority
EC
Ecuador
Prior art keywords
effectors
pharmaceutical use
procedures
preparation
conjugates
Prior art date
Application number
EC2005005626A
Other languages
Spanish (es)
Inventor
Markus Berger
Gerhard Siemeister
Ulrich Klar
Joerg Willuda
Andreas Menrad
Klaus Bosslet
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10234975A external-priority patent/DE10234975A1/en
Priority claimed from DE10305098A external-priority patent/DE10305098A1/en
Application filed by Schering Ag filed Critical Schering Ag
Publication of ECSP055626A publication Critical patent/ECSP055626A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Se describen conjugados de epotilonas y derivados de epotilonas como efectores con biomoléculas adecuadas (como unidades de reconocimiento. Su producción se lleva a cabo haciendo reaccionar los efectores con ligadores adecuados y los compuestos que son producidos se conjugan con las unidades de reconocimiento. Se describe el uso farmacéutico de los conjugados para el tratamiento de procesos neurodegenerativos o asociados con la angiogénesis.Conjugates of epothilones and derivatives of epothilones are described as effectors with suitable biomolecules (as recognition units. Their production is carried out by reacting the effectors with suitable linkers and the compounds that are produced are conjugated with the recognition units. Pharmaceutical use of conjugates for the treatment of neurodegenerative processes or associated with angiogenesis.

EC2005005626A 2002-07-31 2005-02-24 NEW CONJUGATES OF EFFECTORS, PROCEDURES FOR PREPARATION AND PHARMACEUTICAL USE ECSP055626A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10234975A DE10234975A1 (en) 2002-07-31 2002-07-31 New effector conjugates of epithilones useful to treat e.g. diseases associated with proliferative processes, neurodegenerative diseases, multiple sclerosis, Alzheimer's disease and rheumatoid arthritis
DE10305098A DE10305098A1 (en) 2003-02-07 2003-02-07 New effector conjugates of epithilones useful to treat e.g. diseases associated with proliferative processes, neurodegenerative diseases, multiple sclerosis, Alzheimer's disease and rheumatoid arthritis
US45167303P 2003-03-05 2003-03-05

Publications (1)

Publication Number Publication Date
ECSP055626A true ECSP055626A (en) 2005-04-18

Family

ID=31498923

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005626A ECSP055626A (en) 2002-07-31 2005-02-24 NEW CONJUGATES OF EFFECTORS, PROCEDURES FOR PREPARATION AND PHARMACEUTICAL USE

Country Status (16)

Country Link
EP (1) EP1524979A2 (en)
JP (1) JP2006505627A (en)
KR (1) KR20050026033A (en)
AU (1) AU2003253365A1 (en)
BR (1) BR0313043A (en)
CA (1) CA2492437A1 (en)
CO (1) CO5700741A2 (en)
EC (1) ECSP055626A (en)
HR (1) HRP20050186A2 (en)
IL (1) IL166039A0 (en)
IS (1) IS7708A (en)
MX (1) MXPA05001282A (en)
NO (1) NO20051038L (en)
NZ (1) NZ537870A (en)
PL (1) PL374528A1 (en)
WO (1) WO2004012735A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4579351B2 (en) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ Synthesis of epothilone and its intermediates and analogs and uses thereof
IL144370A0 (en) * 1999-02-11 2002-05-23 Schering Ag Epothilon derivatives, method for the production and the use thereof as pharmaceuticals
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
PT1506203E (en) 2002-08-23 2007-04-30 Sloan Kettering Inst Cancer Synthesis of epothilones, intermediates thereto, analogues and uses thereof
GB0221312D0 (en) 2002-09-13 2002-10-23 Novartis Ag Organic compounds
JP2006510626A (en) * 2002-12-05 2006-03-30 シエーリング アクチエンゲゼルシャフト Epothilone analogs for site-specific delivery in the treatment of proliferative diseases
DE10256982A1 (en) 2002-12-05 2004-06-24 Schering Ag New epithilone derivatives are useful for the treatment of diseases associated with proliferative diseases e.g. tumor diseases, inflammatory diseases and neurodegenerative diseases
DK1718340T3 (en) * 2004-01-30 2008-03-03 Bayer Schering Pharma Ag New effector conjugates, processes for their preparation and their pharmaceutical use
US7541330B2 (en) 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
US8288557B2 (en) 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
PE20080102A1 (en) * 2006-05-25 2008-02-11 Bristol Myers Squibb Co AZIRIDINYL-EPOTILONE CONJUGATES AND PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME
AR061181A1 (en) 2006-05-25 2008-08-13 Bristol Myers Squibb Co AZIRIDINIL-EPOTILONE COMPOUNDS
CN101678124A (en) 2007-03-14 2010-03-24 恩多塞特公司 Ligand-linked tubulysin drug delivery conjugates
CN101754969A (en) 2007-05-25 2010-06-23 百时美施贵宝公司 Processes for making epothilone compounds and analogs
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CN101784565B (en) 2007-06-25 2014-12-10 恩多塞特公司 Conjugates containing a hydrophilic spacer linker
CA2703491C (en) 2007-10-25 2017-06-13 Endocyte, Inc. Tubulysins and processes for preparing
IT1401451B1 (en) * 2010-06-10 2013-07-26 Chemi Spa NEW PROCESS OF PREPARATION OF 2-HYDROXY-4-PHENYL-3,4-DIHYDRO-2H-CHROMEN-6-IL-METHANOL E (R) -2- [3- (DIISOPROPYLAMINOUS) -1-PHENYLPROPYL] -4- ( hydroxymethyl) Phenol.
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
AU2013331440A1 (en) 2012-10-16 2015-04-30 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
HUE070615T2 (en) * 2016-10-17 2025-06-28 Pfizer Anti-edb antibodies and antibody-drug conjugates
KR102377416B1 (en) * 2017-06-30 2022-03-21 엘지디스플레이 주식회사 Display Device

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK130984A (en) * 1983-03-07 1984-09-08 Smithkline Beckman Corp Leukotriene antagonists
IL107400A0 (en) * 1992-11-10 1994-01-25 Cortech Inc Bradykinin antagonists
US5942555A (en) * 1996-03-21 1999-08-24 Surmodics, Inc. Photoactivatable chain transfer agents and semi-telechelic photoactivatable polymers prepared therefrom
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
AU2001243372A1 (en) * 2000-03-01 2001-09-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
AU2001295195B2 (en) * 2000-04-28 2007-02-01 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
US6441213B1 (en) * 2000-05-18 2002-08-27 National Starch And Chemical Investment Holding Corporation Adhesion promoters containing silane, carbamate or urea, and donor or acceptor functionality
WO2001092255A2 (en) * 2000-05-26 2001-12-06 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
DE10041221A1 (en) * 2000-08-22 2002-03-14 Deutsches Krebsforsch Process for the preparation of water-soluble saccharide conjugates and saccharide mimetics by the Diels-Alder reaction and their use as therapeutics or diagnostics
GB0116143D0 (en) * 2001-07-02 2001-08-22 Amersham Pharm Biotech Uk Ltd Chemical capture reagent

Also Published As

Publication number Publication date
JP2006505627A (en) 2006-02-16
KR20050026033A (en) 2005-03-14
IS7708A (en) 2005-02-23
AU2003253365A1 (en) 2004-02-23
HRP20050186A2 (en) 2005-10-31
WO2004012735A3 (en) 2004-05-27
BR0313043A (en) 2005-06-14
CA2492437A1 (en) 2004-02-12
PL374528A1 (en) 2005-10-31
NZ537870A (en) 2007-03-30
WO2004012735A2 (en) 2004-02-12
IL166039A0 (en) 2006-01-15
EP1524979A2 (en) 2005-04-27
MXPA05001282A (en) 2005-04-28
CO5700741A2 (en) 2006-11-30
NO20051038L (en) 2005-04-06

Similar Documents

Publication Publication Date Title
ECSP055626A (en) NEW CONJUGATES OF EFFECTORS, PROCEDURES FOR PREPARATION AND PHARMACEUTICAL USE
HN1999000124A (en) SUBSTITUTED PYRAZOLE DERIVATIVES.
UY27878A1 (en) INDOLINFENYL SULFONAMIDE DERIVATIVES
DOP2000000109A (en) THIAZOLILAMIDE DERIVATIVES
UY27571A1 (en) 2-TIO-3, 5-DICIAN-4-PHENYL-6-REPLACED AMINOPIRIDINS AND THEIR USE
CR7673A (en) ANTRANILAMIDOPIRIMIDINAS THAT INHIBIT VEGFR-2 AND VEGFR-3
BR0211905A (en) Rapamycin dialdehydes
PY0219683A (en) AMINO-ALKYL SUBSTITUTED AROMATIC BICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINES
CY1107207T1 (en) NEW ACTIVE COGNITION PRODUCTS, PROCEDURE FOR THEIR PRODUCTION AND PHARMACEUTICAL USE
HN2001000037A (en) DERIVATIVES OF ETERES DE PIRAZOL AS ANTI-INFLAMMATORY / ANALGESIC AGENTS
ES2158876T3 (en) DERIVATIVE OF GALANTAMINE, A PROCEDURE FOR ITS PREPARATION AND ITS USE AS A MEDICINAL PRODUCT.
CR9182A (en) DERIVATIVE OF QUINOLINA, ITS USE, PREPARATION AND MEDICINAL PRODUCT CONTAINING IT
ATE381569T1 (en) EPOTHILONE DERIVATIVES
UY26133A1 (en) SUBSTITUTED DERIVATIVE OF PYRAZOLE.
UY28313A1 (en) NONADEPSIPEPTIDOS ACILADOS
UY26951A1 (en) DERIVATIVES OF OWN ACID
ES2191449T3 (en) DERIVATIVES OF CICLOPENTABENZOFURANO AND ITS USE.
UY27451A1 (en) 2,5-DIAMIDOINDOLES REPLACED AND ITS USE
AR054735A1 (en) PROCESS FOR OBTAINING A PIPERAZINE DERIVATIVE
BRPI0515186A (en) alkylidene-tetrahydronaphthalene derivatives, process for their production and use as an anti-inflammatory
ES2185837T3 (en) USE OF THEOPHYLIN DERIVATIVES FOR THE TREATMENT AND PROFILAXIS OF SHOCK DISEASES, NEW XANTINE COMPOUNDS AND PROCEDURES FOR PRODUCTION.
SV2003001061A (en) NEW HETEROCICLOS 3 REF.LEA 35361-SV
WO2003029217A3 (en) Pyridinic sulfonamide derivatives, method of production and use thereof
ATE275551T1 (en) HALOGENPYRIMIDINES
ECSP044966A (en) FLIBANSERINE STABLE POLYMORPH COMPOSITE, INDUSTRIAL PROCEDURE FOR PREPARATION, AND USE OF IT TO PREPARE MEDICINES